

Body mass index and carpal tunnel syndrome: a Mendelian randomization study

Iyas Daghlas, BS¹; Nathan Varady, BS¹

¹ Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA

Acknowledgements

We are thankful to the authors of the CTS GWAS for making their data available, as well as the following GWAS consortia for providing publically available data: GIANT, GLGC, and DIAGRAM. We want to acknowledge the participants and investigators of the UK Biobank and FinnGen studies.

Abstract word count: 149

Manuscript word count: 2,880

Correspondence for reprint requests:

Iyas Daghlas, BS, Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA

Email: iyas_daghlas@hms.harvard.edu

Running title: BMI and carpal tunnel syndrome

Ethical publication statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure of conflicts of interest: None of the authors has any conflict of interest to disclose.

Abstract

Introduction We investigated whether higher body mass index (BMI) may causally increase risk of carpal tunnel syndrome using Mendelian randomization (MR).

Methods The exposure included genetic instruments comprising independent variants associated with BMI (n=322,154). Associations of these variants with CTS were obtained from a genome-wide association study conducted in UK Biobank (UKB; 12,312 cases/389,344 controls) with replication in the FinnGen cohort (4,505 cases/86,854 controls). Causal effects were estimated using inverse-variance weighted regression, and sensitivity analyses probed robustness of results.

Results A 1-standard deviation (4.7kg/m²) increase in genetically instrumented BMI increased the odds of CTS in UKB (OR 1.73, 95% CI 1.48-2.02, $P=2.68 \times 10^{-12}$; 16.8 additional cases per 1000 person-years [95% CI 11.0-23.5]). This effect was consistent in the replication sample and across sensitivity analyses.

Discussion These data support a causal effect of higher BMI on susceptibility to CTS. Clinical investigations of weight loss for treatment of CTS may be warranted.

Key words: Mendelian randomization, carpal tunnel syndrome, body mass index, obesity, entrapment neuropathy

Introduction

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, with an estimated prevalence ranging from 1-5%¹. CTS accounts for a large proportion of lost work time related to disabling injuries, and medical care for CTS has been estimated to cost more than \$2 billion annually². In light of this clinical and economic burden of disease, efforts have been made to delineate modifiable factors contributing to risk of CTS³.

Elevated body mass index (BMI), a measure of overall adiposity, has consistently emerged as a modifiable risk factor for CTS³. A meta-analysis of 58 observational studies related obesity to a doubling in odds of CTS⁴. However, given the observational nature of these studies, it is unclear whether this association is causal⁵. For instance, BMI is influenced by many underlying health conditions such as hypothyroidism⁶, which may confound the relationship of obesity with CTS. Establishing evidence for a causal effect of higher BMI on CTS would strengthen the case for investment in trials investigating weight loss for treatment of CTS.

Limitations to causal inference in observational research may be overcome by an instrumental variable method called 'Mendelian randomization' (MR)⁷. MR uses genetic variants as proxies for epidemiologic exposures (e.g. BMI) to test for causal effects on outcomes (e.g. CTS). This method leverages the random assortment of genetic variants at gametogenesis which, at the population level, randomly allocates individuals to different levels of any given heritable exposure. This random allocation substantially

reduces confounding and minimizes the impact of reverse causality when testing epidemiologic relationships⁵. We thus leveraged MR to determine whether higher BMI causally increased CTS risk.

Methods

Overall study design

We implemented a two-sample MR study design. Two-sample MR uses genetic variants to estimate the causal effect of a given exposure on an outcome. Non-overlapping samples are used to measure the variant-exposure and variant-outcome effect. Three key assumptions must be met for unbiased causal effect estimation in MR: 1) genetic variants must be strongly associated with the exposure, 2) the association of the genetic variant with the exposure or outcome must not be confounded, and 3) the genetic variants must only affect the outcome through the exposure of interest⁵. These three assumptions are addressed in turn below.

Exposures and mediators

To identify genetic instrumental variables proxying effects of BMI, we drew upon genome-wide association studies (GWAS) conducted by the Genetic Investigation of ANthropometric Traits (GIANT) consortium. This comprised a meta-analysis across 80 cohorts, collectively contributing data on up to 322,154 participants of European ancestry⁸. The per-allele effects of the variants on BMI are reported in relation to a 1-standard deviation (SD) increase in BMI, corresponding to 4.7 kg/m². This approximately represents the transition from overweight to obesity.

As some observational evidence suggests that higher central adiposity may also independently increase CTS risk⁴, we tested waist-to-hip ratio adjusted for BMI (WHRadjBMI), a validated measure of central adiposity⁹, as an exposure in secondary analyses. The genetic association study for WHRadjBMI comprised a meta-analysis across 101 cohorts, collectively contributing data on up to 210,088 participants of European ancestry⁹. Here, a 1-SD change represents 0.08 units of WHRadjBMI. The genetic instruments for both BMI and WHRadjBMI have been validated in independent cohorts^{10,11}.

We also tested whether the effects of BMI on CTS were attributable to the effects of BMI on blood lipids (low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglycerides) or on type 2 diabetes (T2D), both of which are influenced by BMI^{12,13} and are putative risk factors for CTS^{14,15}. Although there are larger T2D GWAS available³¹, this dataset was selected to avoid sample overlap with UKB. Details on the genetic association studies for these mediators are provided in Table 1.

[Table 1]

Outcome dataset

The outcome data source was a GWAS of carpal tunnel syndrome (CTS) conducted using the population-based UK Biobank (UKB) cohort. Details regarding the UKB cohort

design and population have been previously reported¹⁶. Approximately 500,000 participants were recruited across 22 assessment centers from 2006-2010. At baseline assessment, the volunteers completed a standardized questionnaire and interview with a study nurse, and blood was collected for genotyping.

Cases of CTS were defined as UKB participants meeting any of the following criteria: self-reported history of CTS, ICD-10 code for CTS, operation code for carpal tunnel release or revision of carpal tunnel release, and self-reported history of carpal tunnel surgery. Identification of CTS cases in the UKB through routine health record data has been validated to have a high positive predictive value as compared to manual record review by experienced clinicians¹⁷. In total, 12,312 CTS cases and 389,344 controls of European ancestry with suitable genetic data were identified for analysis. The contribution of each data source to the total case count has been previously reported¹⁸, with the ICD-10 code G560 contributing the greatest number of cases (n=9,139). GWAS was conducted using BOLT-LMM to account for relatedness within the UKB cohort, with linear regression beta coefficients converted to log-odds using the prevalence of CTS in UKB¹⁸.

We sought to replicate the effect of BMI on CTS using publicly available CTS GWAS summary statistics from the FinnGen consortium. Details on genotyping and imputation are available online (see Data Links at end of manuscript). In brief, samples were genotyped with Illumina and Affymetrix arrays, imputed using the SISu population-specific reference panel, and analyzed using the SAIGE¹⁹ GWAS software to account

for sample relatedness. CTS cases were exclusively identified using ICD codes (ICD-9: 3540; ICD-10: G560) contributed by nationwide Finnish registries. In total, there were 4,505 CTS cases and 86,854 controls.

Selection of genetic instrumental variables and data harmonization

We extracted variants associated with BMI at genome-wide significance from the GWAS summary statistics file ($p < 5 \times 10^{-8}$). This threshold corresponds to an F-statistic of 30, which is greater than the accepted cutoff of 10 to mitigate weak instrument bias, and hence satisfies the MR assumption that the genetic instrument has a strong association with the exposure (i.e. the ‘relevance assumption’)⁵. From this variant list, we identified variants also present in the CTS GWAS that could be matched on the basis of allele frequency, and harmonized the SNP-exposure associations with the SNP-outcome associations by matching effect alleles. To generate a set of independent genetic variants, we clumped this set of variants to a between-SNP linkage disequilibrium cutoff of r^2 of 0.001 using the 1,000 Genomes European reference panel implemented in the TwoSampleMR package²⁰. This approach for identifying variants for use as instrumental variables was taken for WHRadjBMI and each of the considered mediators.

This variant selection procedure identified 69 independent SNPs for use as instrumental variables for BMI. Using previously described methods for summarized data²¹, we determined that these variants collectively explained 2.27% of the variance in BMI. Using this variance estimate in the mRnd power calculator²², we determined that our

study had 80% power to detect a causal OR of 1.17 for CTS. Notably, the percent variance explained informs the power, but not validity, of the MR analysis.

Primary MR analyses

To estimate the causal effect of BMI on CTS risk, we regressed the SNP-CTS associations on the SNP-exposure associations, and weighted the effects by the inverse of the variance (IVW) of the SNP-CTS association under a random-effects model with the intercept constrained at the origin²³. The estimated odds ratio approximates the relative risk given the population prevalence of CTS in UKB, which permitted conversion of effect estimates to absolute risk increases using the following equation¹¹: absolute risk increase per 1-SD increase in exposure = [OR-1] x [absolute incidence]. Incidence estimates used for absolute risk calculations were obtained from a pooled analysis of US working populations, as part of the upper-extremity musculoskeletal disorder consortium (23 CTS cases per 1000 person-years²⁴).

Sensitivity analyses for horizontal pleiotropy

In addition to the assumption that the SNPs are strongly associated with the exposure of interest, there are two assumptions required for valid causal inference in Mendelian randomization. First, the genetic associations must not be confounded by factors that influence both genotype and the phenotype of interest. This is unlikely to be a major bias given the random allocation of genetic variants at gametogenesis^{5,25} and our use of data from GWAS that have carefully controlled for population stratification (Table 1). Population stratification is defined as systematic differences in allele frequencies

between cases and controls which are attributable due to differences in ancestry rather than direct effects of genes on disease. Second, the genetic variants associated with the exposure must not influence the outcome through pathways independent of the exposure of interest. This is the strongest assumption of MR, and is violated in the setting of horizontal pleiotropy. We therefore conducted a range of sensitivity analyses that produce unbiased estimates under various forms of pleiotropy. The robust, heterogeneity-penalized IVW method down weights the influence of heterogeneous, potentially pleiotropic, SNPs²⁶. MR-Egger models an intercept term in the IVW regression that captures potential unbalanced horizontal pleiotropy²⁷. In addition to producing an effect estimate, the MR Egger intercept estimate provides a measure of unbalanced horizontal pleiotropy. The weighted median estimator provides consistent causal effect estimation when up to 50% of the variants are pleiotropic²⁸. Finally, we utilized the Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) method to detect and remove potentially pleiotropic variants²⁹. We considered consistent effects across sensitivity analyses to strengthen evidence for causality.

Assessment of mediation through cardiometabolic risk factors

We aimed to determine whether any of the observed effect of BMI on CTS may be attributable to its effects on T2D or blood lipids. To do so, we first tested for effects of the putative mediators with CTS in univariable MR. Consistent with prior work utilizing binary exposures in MR, the effect of diabetes liability on CTS was scaled to represent a doubling in the odds of diabetes³². For mediators with an identified effect in univariable

MR, we conducted regression-based multivariable³³ MR accounting for the effect of BMI on CTS through the mediator (e.g. BMI → T2D → CTS). We considered an attenuation in the BMI coefficient to be consistent with mediation through the risk factor of interest. As previously recommended for mediation analysis involving dichotomous outcomes in MR³⁴, we report the total (from univariable MR) and direct (from multivariable MR) effects of BMI.

Software and statistical analysis

All analyses were conducted using R version 3.5.0. We utilized the TwoSampleMR²⁰ and MendelianRandomization³⁵ packages. All statistical tests were two-sided.

Standard Protocol Approvals, Registrations, Patient Consents, and Data availability

This study used precompiled, publically available, de-identified data provided by genetic consortia and therefore did not require IRB approval. Informed consent was obtained from all participants in contributing studies. All data used in this study are publicly available at the links provided at the end of the manuscript.

Results

[Figure 1]

Mendelian randomization supports a causal effect of BMI on risk of CTS

A 1-SD increase in BMI increased risk of CTS (OR 1.73, 95% CI 1.48-2.02, $P=2.68 \times 10^{-12}$; Figure 1). This effect corresponds to an absolute risk increase of 16.8 additional CTS cases per 1000 person years [95% CI 11.0-23.5]. This effect replicated in the independent FinnGen cohort (OR 1.62, 95% CI 1.30-2.02, $P=1.58 \times 10^{-5}$). In contrast, a 1-SD increase in WHRadjBMI was not associated with CTS in UKB (OR 1.01, 0.76-1.34, $P=0.97$; Table 1).

Sensitivity analyses do not indicate that the causal effect of BMI on CTS is driven by horizontal pleiotropy

[Figure 2]

As there was evidence of heterogeneity in the causal effect of BMI on CTS ($P=6.7 \times 10^{-4}$), we conducted sensitivity analyses to assess whether the effect of genetically predicted BMI on CTS may be biased by pleiotropy. First, the MR Egger intercept, a measure of unbalanced horizontal pleiotropy, did not differ from the null (Beta = -0.01, $P=0.21$). Second, all three models used in sensitivity analyses provided consistent results (Figure 2). Third, the MR-PRESSO method did not detect any potentially pleiotropic outlier variants in the BMI instrument. Thus, the primary MR result is unlikely to be biased by horizontal pleiotropy.

Type 2 diabetes partially mediates the effect of BMI on CTS

[Table 2]

Having established a robust effect of higher BMI on increased risk of CTS, we tested whether any portion of this total effect was attributable to knock-on effects of higher BMI on blood lipids or diabetes risk. Liability to T2D increased risk of CTS (OR 1.08, 95% CI 1.03-1.11, $P=5.20 \times 10^{-5}$), with consistent effects in pleiotropy-robust sensitivity analyses (Figure 2). The effect of higher BMI on CTS was partially attenuated in multivariable MR when accounting for mediation through T2D (1.53, 95% CI 1.38-1.68, $P=2.85 \times 10^{-8}$; Table 1). In contrast, the effects of blood lipids on CTS were null, suggesting that any effect of BMI on lipids is not responsible for its role in causing CTS.

Discussion

While numerous observational studies have found elevated BMI to be associated with CTS⁴, whether BMI plays any causal role in CTS risk has remained unknown. Using a pseudo-randomized study design, we found strong evidence for a causal link between higher BMI and increased risk of CTS. Furthermore, we replicated these results in an independent sample and found the effects to be consistent across a range of sensitivity analyses assessing potential violations of the MR assumptions. We also provide mechanistic evidence for how BMI may exert this effect on CTS, namely through its role in causing T2D. Taken together, these results substantially enhance our understanding of BMI as a key CTS risk factor and have a number of implications in the prevention and treatment of CTS.

The most important finding of this study was the strong evidence that higher BMI causally increased risk of CTS. The present analysis is able to overcome potential biases of prior observational studies by utilizing genetic variants as proxies for higher BMI. Specially, given the random allocation of genetic variants at gametogenesis^{5,36} and the study-specific control for confounding by population stratification, our results are unlikely to be biased by confounding or reverse causality. Consequently, these results greatly strengthen the case for investment in trials investigating weight loss for treatment of CTS. Furthermore, in considering the increasing rates of obesity in adults³⁷, our results may partly explain the rising CTS incidence³⁸. Population-level efforts to address the obesity epidemic may therefore have substantial benefits in stemming the increase in rates of CTS.

Our results inform the mechanistic understanding of how BMI influences CTS by identifying mediation through T2D. Type 2 diabetes is observationally associated with CTS¹⁴, potentially through increased oxidative stress and extracellular protein glycation⁴. In univariable MR we found evidence to suggest that this effect is causal, with no evidence for bias by horizontal pleiotropy. In multivariable MR we found evidence suggesting that part of the effect of BMI on CTS is accounted for by T2D. However, the direct effect of BMI on CTS independently of T2D remained significant (OR 1.53). Therefore, obese populations remain at elevated risk for CTS regardless of their T2D status. In contrast, other dimensions of metabolic health including central adiposity proxied by WHRadjBMI and circulating lipids did not have a causal relationship with CTS. Thus, apart from T2D, these results do not support

cardiometabolic risk as a strong contributor to CTS. Furthermore, these results do not implicate LDL-c lowering as a causal risk factor for peripheral neuropathies, as has previously been suggested³⁹. Observational associations relating lipids to risk of CTS may have been driven by residual confounding, potentially through BMI or T2D¹⁵.

Having established a likely role for higher BMI in the etiology of CTS, it is plausible that weight loss may be a feasible strategy for prevention or treatment of CTS. Indeed, a longitudinal study of patients undergoing bariatric surgery found lower rates of CTS after bariatric surgery⁴⁰. However, the mechanisms by which this effect of BMI may operate independently of T2D remains speculative. A direct compressive effect of adipose tissue within the carpal tunnel, or of increased hydrostatic pressure throughout the carpal canal due to surrounding adipose tissue⁴¹, has been suggested⁴. Alternatively, the link may be explained through increased endoneurial edema⁴² or through increased rates of hand osteoarthritis⁴³ in obese populations⁴⁴.

The major strength of this analysis is the use of MR, with consistent results across sensitivity analyses. The use of non-overlapping samples for measurement of genetic associations with the exposure and outcome avoids biases related to sample overlap⁴⁵. Finally, independent replication lends further support to the robustness of the reported association. This is particularly relevant to UKB, which may be biased due to the relative healthiness of the study participants⁴⁶. There are limitations to acknowledge. First, these findings relate to CTS etiology rather than progression or severity. Testing such effects would necessitate a GWAS of clinical progression, severity, or of measures derived

from electrodiagnostic testing⁴⁷. Second, horizontal pleiotropy may bias the causal effects⁵; however, our results were consistent across a range of sensitivity analyses suggesting this is an unlikely explanation. Third, CTS may be under-reported in UKB, which may result in an underestimation of the true causal effect in our analyses (i.e. bias towards the null). Fourth, we did not conduct analyses stratified by sex due to lack of available sex-stratified GWAS. Indeed, it is plausible that the effect of higher body mass index differs by sex, as female sex is a risk factor for CTS⁴⁴.

In conclusion, these results are consistent with a causal effect of higher BMI on increased risk of CTS. Clinical investigations of weight loss in the management of CTS may be warranted.

Data links

CTS GWAS: https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-019-08993-6/MediaObjects/41467_2019_8993_MOESM6_ESM.txt

BMI and WHRadjBMI GWAS:

https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files

GLGC GWAS: <http://lipidgenetics.org/>

DIAGRAM GWAS: <https://www.diagram-consortium.org/>

FinnGen GWAS: <https://finngen.gitbook.io/finngen-documentation/-LvQ4yR2YFUM5eFTjieO/>

mRnd power calculator: <http://cnsgenomics.com/shiny/mRnd/>

Conflicts of interest

The authors declare no conflicts of interest.

Funding

This study was performed without financial support.

References

1. Atroshi I. Prevalence of Carpal Tunnel Syndrome in a General Population. *JAMA* 1999; **282**:153. Published online: July 14, 1999. DOI: 10.1001/jama.282.2.153.
2. Calandruccio JH, Thompson NB. Carpal Tunnel Syndrome: Making Evidence-Based Treatment Decisions. *Orthopedic Clinics of North America* 2018; **49**:223–229. Published online: 2018. DOI: 10.1016/j.ocl.2017.11.009.
3. Padua L, Coraci D, Erra C, Pazzaglia C, Paolasso I, Loreti C, *et al.* Carpal tunnel syndrome: clinical features, diagnosis, and management. *The Lancet Neurology* 2016; **15**:1273–1284. Published online: 2016. DOI: 10.1016/S1474-4422(16)30231-9.
4. Shiri R, Pourmemari MH, Falah-Hassani K, Viikari-Juntura E. The effect of excess body mass on the risk of carpal tunnel syndrome: A meta-analysis of 58 studies. *Obesity Reviews* 2015; **16**:1094–1104. Published online: 2015. DOI: 10.1111/obr.12324.
5. Davies NM, Holmes M V., Davey Smith G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. *BMJ (Online)* 2018; **362**. Published online: 2018. DOI: 10.1136/bmj.k601.
6. Bland JDP. The relationship of obesity, age, and carpal tunnel syndrome: More complex than was thought? *Muscle and Nerve* 2005; **32**:527–532. Published online: 2005. DOI: 10.1002/mus.20408.
7. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology* 2003; **32**:1–22. Published online: February 2003. DOI:

- 10.1093/ije/dyg070.
8. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015; **518**:197–206. Published online: February 12, 2015. DOI: 10.1038/nature14177.
 9. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, *et al.* New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 2015; **518**:187–196. Published online: February 12, 2015. DOI: 10.1038/nature14132.
 10. Lyall DM, Celis-Morales C, Ward J, Iliodromiti S, Anderson JJ, Gill JMR, *et al.* Association of Body Mass Index With Cardiometabolic Disease in the UK Biobank. *JAMA Cardiology* 2017; **2**:882. Published online: August 1, 2017. DOI: 10.1001/jamacardio.2016.5804.
 11. Emdin CA, Khera A V., Natarajan P, Klarin D, Zekavat SM, Hsiao AJ, *et al.* Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. *JAMA* 2017; **317**:626. Published online: February 14, 2017. DOI: 10.1001/jama.2016.21042.
 12. Holmes M V., Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, *et al.* Causal effects of body mass index on cardiometabolic traits and events: A Mendelian randomization analysis. *American Journal of Human Genetics* 2014; **94**:198–208. Published online: 2014. DOI: 10.1016/j.ajhg.2013.12.014.
 13. Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, *et al.* Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian

- Randomization Analysis. *Circulation* 2017; **135**:2373–2388. Published online: 2017. DOI: 10.1161/CIRCULATIONAHA.116.026560.
14. Pourmemari MH, Shiri R. Diabetes as a risk factor for carpal tunnel syndrome: A systematic review and meta-analysis. *Diabetic Medicine* 2016; **33**:10–16. Published online: 2016. DOI: 10.1111/dme.12855.
 15. Nakamichi KI, Tachibana S. Hypercholesterolemia as a risk factor for idiopathic carpal tunnel syndrome. *Muscle and Nerve* 2005; **32**:364–367. Published online: 2005. DOI: 10.1002/mus.20363.
 16. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018; **562**:203–209. Published online: October 10, 2018. DOI: 10.1038/s41586-018-0579-z.
 17. Lane J, Schnier C, Green J, Lam W, Furniss D, Sudlow C. Can we use routinely collected hospital and GP data for epidemiological study of common hand conditions? A UK Biobank based validation project. *bioRxiv* 2018. Published online: 2018. DOI: <https://doi.org/10.1101/274167>.
 18. Wiberg A, Ng M, Schmid AB, Smillie RW, Baskozos G, Holmes M V., *et al.* A genome-wide association analysis identifies 16 novel susceptibility loci for carpal tunnel syndrome. *Nature Communications* 2019; **10**:1–12. Published online: 2019. DOI: 10.1038/s41467-019-08993-6.
 19. Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nature Genetics* 2018; **50**:1335–1341.

- Published online: 2018. DOI: 10.1038/s41588-018-0184-y.
20. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* 2018; **7**:e34408. Published online: May 30, 2018. DOI: 10.7554/eLife.34408.
 21. Valdes-Marquez E, Parish S, Clarke R, Stari T, Worrall BB, Hopewell JC. Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study. *Neurology* 2019; **92**:E1176–E1187. Published online: 2019. DOI: 10.1212/WNL.0000000000007091.
 22. Brion MJA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *International Journal of Epidemiology* 2013; **42**:1497–1501. Published online: 2013. DOI: 10.1093/ije/dyt179.
 23. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Statistical Methods in Medical Research* 2017; **26**:2333–2355. Published online: 2017. DOI: 10.1177/0962280215597579.
 24. Dale AM, Harris-Adamson C, Rempel D, Gerr F, Hegmann K, Silverstein B, *et al.* Prevalence and incidence of carpal tunnel syndrome in US working populations: pooled analysis of six prospective studies. *Scandinavian Journal of Work, Environment & Health* 2013; **39**:495–505. Published online: September 2013. DOI: 10.5271/sjweh.3351.
 25. Smith GD, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. *PLoS Medicine* 2007; **4**:1985–1992. Published online: 2007. DOI: 10.1371/journal.pmed.0040352.

26. Rees JMB, Wood AM, Dudbridge F, Burgess S. Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates. Onland-Moret NC, editor. PLOS ONE 2019; **14**:e0222362. Published online: September 23, 2019. DOI: 10.1371/journal.pone.0222362.
27. Bowden J, Smith GD, Burgess S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. International Journal of Epidemiology 2015; **44**:512–525. Published online: 2015. DOI: 10.1093/ije/dyv080.
28. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology 2016; **40**:304–314. Published online: 2016. DOI: 10.1002/gepi.21965.
29. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics 2018; **50**:693–698. Published online: May 23, 2018. DOI: 10.1038/s41588-018-0099-7.
30. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, *et al.* An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. Diabetes 2017; **66**:2888–2902. Published online: 2017. DOI: 10.2337/db16-1253.
31. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nature Genetics 2018; **50**:1505–1513. Published online: November 8, 2018. DOI: 10.1038/s41588-018-0241-6.

32. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. *European Journal of Epidemiology* 2018; **33**:947–952. Published online: 2018. DOI: 10.1007/s10654-018-0424-6.
33. Burgess S, Thompson SG. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. *American Journal of Epidemiology* 2015; **181**:251–260. Published online: 2015. DOI: 10.1093/aje/kwu283.
34. Burgess S, Thompson DJ, Rees JMB, Day FR, Perry JR, Ong KK. Dissecting causal pathways using mendelian randomization with summarized genetic data: Application to age at menarche and risk of breast cancer. *Genetics* 2017; **207**:481–487. Published online: 2017. DOI: 10.1534/genetics.117.300191.
35. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *International Journal of Epidemiology* 2017; **46**:1734–1739. Published online: December 1, 2017. DOI: 10.1093/ije/dyx034.
36. Smith GD, Ebrahim S. “Mendelian randomization”: Can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology* 2003; **32**:1–22. Published online: 2003. DOI: 10.1093/ije/dyg070.
37. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016. *JAMA* 2018; **319**:1723. Published online: April 24, 2018. DOI:

- 10.1001/jama.2018.3060.
38. Gelfman R, Melton LJ, Yawn BP, Wollan PC, Amadio PC, Stevens JC. Long-term trends in carpal tunnel syndrome. *Neurology* 2009; **72**:33–41. Published online: 2009. DOI: 10.1212/01.wnl.0000338533.88960.b9.
 39. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. *Annals of Pharmacotherapy* 2003; **37**:274–278. Published online: 2003. DOI: 10.1177/106002800303700220.
 40. Hooper MM, Stellato TA, Hallowell PT, Seitz BA, Moskowitz RW. Musculoskeletal findings in obese subjects before and after weight loss following bariatric surgery. *International Journal of Obesity* 2007; **31**:114–120. Published online: 2007. DOI: 10.1038/sj.ijo.0803349.
 41. Werner RA, Albers JW, Franzblau A, Armstrong TJ. The relationship between body mass index and the diagnosis of carpal tunnel syndrome. *Muscle & Nerve* 1994; **17**:632–636. Published online: 1994. DOI: 10.1002/mus.880170610.
 42. Werner RA, Jacobson JA, Jamadar DA. Influence of body mass index on median nerve function, carpal canal pressure, and cross-sectional area of the median nerve. *Muscle and Nerve* 2004; **30**:481–485. Published online: 2004. DOI: 10.1002/mus.20125.
 43. Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, Van Osch G, *et al.* Association between weight or body mass index and hand osteoarthritis: A systematic review. *Annals of the Rheumatic Diseases* 2010; **69**:761–765. Published online: 2010. DOI: 10.1136/ard.2008.106930.
 44. Pourmemari M-H, Heliövaara M, Viikari-Juntura E, Shiri R. Carpal tunnel release:

- Lifetime prevalence, annual incidence, and risk factors. *Muscle & Nerve* 2018; **58**:497–502. Published online: October 2018. DOI: 10.1002/mus.26145.
45. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genetic Epidemiology* 2016; **40**:597–608. Published online: 2016. DOI: 10.1002/gepi.21998.
46. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *American Journal of Epidemiology* 2017; **186**:1026–1034. Published online: November 1, 2017. DOI: 10.1093/aje/kwx246.
47. Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. *PLoS Genetics* 2017; **13**:1–9. Published online: 2017. DOI: 10.1371/journal.pgen.1006944.

Table 1. GWAS datasets contributing genetic association estimates for use in MR

analysis. LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein

cholesterol; PCs: principal components of ancestry; T2D: type 2 diabetes.

Analysis	Phenotype	Ancestry (n_{total} or n_{cases} / n_{controls})	Correction for population stratification	Phenotype unit
Primary	Body mass index ⁸	European (322,154)	PCs, double genomic control	1-standard deviatric (4.7kg/m ²)
	Carpal tunnel syndrome ¹⁸	European (12,312 / 389,344)	BOLT-LMM ¹	Log-odds
Secondary	Waist-to-hip ratio adjusted for BMI ⁹	European (210,088)	Double genomic control	1-standard deviatric (0.08 units)
	Type 2 Diabetes ³⁰	European (26,676 / 132,532)	PCs	Log-odds
	LDL-c	European (173,082)	PCs, double genomic control	1-standard deviatric (38.7mg/dL)
	HDL-c	European (187,167)	Principal components, double genomic control	1-standard deviatric (15.5mg/dL)
	Triglycerides	European (177,861)	PCs, double genomic control	1-standard deviatric (41mg/dL)

¹Population structure is taken into account by use of a linear mixed model.

Table 2. Inverse-variance weighted and multivariable MR effects of BMI and mediators on carpal tunnel syndrome in UK Biobank. LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; PCs: principal components of ancestry; T2D: type 2 diabetes.

Exposure	<i>n</i> SNPs in instrument	Odds ratio [95% CI]	P value
Univariable MR			
BMI	69	1.73 [1.48-2.02]	2.68×10^{-12}
T2D ^b (mediator)	37	1.08 [1.04-1.11]	5.20×10^{-5}
LDL-c (mediator)	77	1.04 [0.96-1.12]	0.35
HDL-c (mediator)	87	1.02 [0.93-1.13]	0.62
Triglycerides (mediator)	56	1.04 [0.93-1.16]	0.53
Multivariable MR ^a			
BMI adj. T2D	97	1.53 [1.38-1.68]	2.85×10^{-8}
T2D ^b adj. BMI	97	1.07 [1.04-1.10]	7.83×10^{-5}

BMI: body mass index; CI: confidence interval; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; SNP: single nucleotide polymorphism; T2D: type 2 diabetes

^aMultivariable MR was only conducted when univariable MR demonstrated evidence of a causal effect.

^bThe effect is provided in relation to a doubling in the odds of T2D.




Figure 1. Scatter-plot of BMI-increasing variants and their effects on carpal tunnel syndrome (CTS). The x-axis shows the variant effects on BMI (standard deviation units), and the y-axis shows the variant effects on CTS (log-odds). The regression line represents the inverse-variance weighted regression of CTS on BMI, with the slope representing the estimate of the casual effect.

BMI and carpal tunnel syndrome




Figure 2. Mendelian randomization sensitivity analyses for the effect of genetically instrumented BMI (per standard deviation increase) and T2D^a liability on odds of carpal tunnel syndrome (CTS). Bars represent 95% confidence intervals.

BMI: body mass index; CI: confidence interval; OR: odds ratio; SD: standard deviation;

T2D: type 2 diabetes

^aUnits of the exposure are a doubling in the odds of T2D.